Graham Richards is a chemist and EmeritusFellow of Brasenose College, Oxford. He served as head of the department of chemistry at the University of Oxford from 1997 to 2006. Richards is a pioneer in the field of computer-aided molecular design, in particular its application to the pharmaceuticals industry. He was the founding scientist of Oxford Molecular Ltd., and introduced a novel model for the funding of research at Oxford University, which has been copied elsewhere. Richards has published more than 300 scientific papers, including 15 books.
Education
Graham Richards was born 1 October 1939 in Hoylake, England, to Percy and Gwendoline Julia Richards. Both parents were of Welsh extraction. Richards was educated at Birkenhead School. Richards won a scholarship to Brasenose College, Oxford, starting his studies there in 1958. Richards received his bachelor's degree in Chemistry with first class honors from the University of Oxford in 1961. Richards then studied the electronic spectroscopy of diatomic molecules with Richard F. Barrow, earning his Master of Arts and Doctor of Philosophy degrees from the University of Oxford in 1964.
Career and research
After his PhD, he continued his spectroscopic work with fellowships in Oxford and Paris, France. Graham Richards soon returned to Oxford as a research fellow at Balliol College, Oxford. He was promoted to a lecturer at Oxford University, to reader, and to professor. He served as chairman of the chemistry department from 1997-2006. Richards celebrated his formal retirement from the University of Oxford on 18 May 2007. He is now an Emeritus fellow of Brasenose College.
Industry involvement
In the fourth year of his degree course Richard's research project led him to using Oxford's Ferranti Mercury computer to solve integrals. During a fellowship year in France at Centre de Mécanique Ondulatoire Appliquée, he was able to use more powerful computers. Returning to Oxford, he worked on ab initio computations and applied computational techniques to solving quantum mechanical problems in theoretical chemistry, in particular studying spin-orbit coupling. His influential paper Third age of quantum chemistry marked the development of computational techniques for theoretical analysis whose precision equaled or surpassed experimental results. Richards saw the potential to apply computer techniques for examining the structure and properties of compounds in the area of pharmaceutical applications. He became a pioneer in the field of computer-aided molecular design. He was the first to produce coloured images modelling molecular structure graphically, and introduced many of the techniques now widely used in academia and industry. In 1982, Richards became a founding member of the Molecular Graphics Society. The society started the Journal of Molecular Graphics in 1983. Richards served as the editor-in-chief of the journal from 1984 to 1996. The journal's name changed to Journal of Molecular Graphics and Modelling in 1997. In 1989 Richards was the scientific co-founder of Oxford Molecular Limited. The company developed software for modelling of small molecules and proteins, and drug design. The company was possible in part because of economic and legal changes under the government of Margaret Thatcher that enabled British universities to become involved with venture capital and technology transfer. As Oxford Molecular Group, Ltd. the company was floated on the London Stock Exchange in 1992, making the university £10 million. The company was worth £450 million at its peak but was eventually sold for £70 million. It was one of several companies that combined to form Accelrysin 2001. Richards was instrumental in raising £64 million to fund a new laboratory for Oxford University through an innovative funding approach. £20 million worth of funding began with an "unusual collaboration" between Graham and David Norwood. Norwood then arranged for Beeson-Gregory to provide £20 million in exchange for half the University's equity share of any spin-out companies emanating from the Chemistry Department for 15 years. In 2003, Beeson-Gregory and Evolution Group merged, later creating a subsidiary, IP2IPO. Graham formed the spin-out company InhibOx Ltd. in 2001. InhibOx applied cloud computing techniques to computational chemistry and drug discovery, and developed a searchable database of small-molecules called Scopius. In 2002, Richards donated his shares, twenty-five percent of the company, to the National Foundation for Cancer Research. In 2017, InhibOx relaunched as Oxford Drug Design Ltd., with a new focus on antibiotic discovery. Richards joined the Science Advisory Panel of Oxford Medical Diagnostics. Richards is a non-executive director of IP Group plc, having also served as its chairman.
Richards was married to his first wife, Jessamy Kershaw on 12 December 1970. She died of cancer in November 1988. As of 5 October 1996, Richards married Mary Elizabeth Phillips, director of research planning at University College London. He has two sons and three stepchildren.
